

Library

The University of Bradford Institutional Repository

http://bradscholars.brad.ac.uk

This work is made available online in accordance with publisher policies. Please refer to the repository record for this item and our Policy Document available from the repository home page for further information.

To see the final version of this work please visit the publisher's website. Access to the published online version may require a subscription.

Link to publisher's version: https://doi.org/10.1016/j.ejmech.2017.08.046

Citation: Pippione AC, Giraudo A, Bonanni D et al (2017) Hydroxytriazole derivatives as potent and selective aldo-keto reductase1C3 (AKR1C3) inhibitors discovered by bioisosteric scaffold hopping approach. European Journal of Medicinal Chemistry. 139: 936-946.

Copyright statement: © 2017 Elsevier. Reproduced in accordance with the publisher's selfarchiving policy. This manuscript version is made available under the *CC-BY-NC-ND 4.0 license*.



Hydroxytriazole Derivatives as Potent and Selective Aldo-keto Reductase 1C3 Inhibitors Discovered by Bioisosteric Scaffold Hopping Approach

Agnese C. Pippione,¹ Alessandro Giraudo,¹ Davide Bonanni,¹ Irene M. Carnovale,¹ Elisabetta Marini,¹ Clara Cena,¹ Annalisa Costale,¹ Daniele Zonari,¹ Klaus Pors,² Maria Sadiq,² Donatella Boschi,¹ Simonetta Oliaro-Bosso¹* and Marco L. Lolli.¹*

¹ Department of Science and Drug Technology, University of Torino, via Pietro Giuria 9, 10125 Torino (Italy).

² Institute of Cancer Therapeutics, Faculty of Life Sciences, University of Bradford, West Yorkshire BD7 1DP (UK).

Keywords

Aldo-keto reductase 1C3; AKR1C3; 17β-HSD5; Prostate cancer; CRPC; bioisosterism; scaffold hopping; inhibitors.

Abstract

The aldo-keto reductase 1C3 isoform (AKR1C3) plays a vital role in the biosynthesis of androgens, making this enzyme an attractive target for castration-resistant prostate cancer (CRPC) therapy. Although AKR1C3 is a promising drug target, no AKR1C3-targeted agent has to date been approved for clinical use. Flufenamic acid, a non-steroidal anti-inflammatory drug, is known to potently inhibit AKR1C3 in a non-selective manner as COX off-target effects are also observed. To diminish off-target effects, we have applied a scaffold hopping strategy replacing the benzoic acid moiety of flufenamic acid with an acidic hydroxyazolecarbonylic scaffold. In particular, differently N-substituted hydroxylated triazoles were designed to simultaneously interact with both subpockets 1 and 2 in the active site of AKR1C3 isoform, larger for AKR1C3 than other AKR1Cs isoforms. Through computational design and iterative rounds of synthesis and biological evaluation, novel compounds are reported, sharing high selectivity (up to 230-fold) for AKR1C3 over 1C2 isoform and minimal COX1 and COX2 off-target inhibition. A docking study of compound 8, the most interesting compound of the series, suggested that its methoxybenzyl substitution has the ability to fit inside subpocket 2, being involved in π - π staking interaction with Trp227 (partial overlapping) and in a T-shape π - π staking with Trp86. This compound was also shown to diminish testosterone production in the AKR1C3-expressing 22RV1 prostate cancer cell line while synergistic effect was in combination with abiraterone and enzalutamide.

1. Introduction

Prostate cancer (PCa) is the most commonly diagnosed cancer in men and the second leading cause of death.[1] Individuals diagnosed with high-risk prostate cancer are typically treated with surgery or a combination of radiation and androgen deprivation therapy (ADT). Many will inevitably relapse and ultimately develop castration-resistant prostate cancer (CRPC), which is responsible for the vast majority of PCa mortalities. Accordingly, there is an unmet clinical need to develop new therapies for the treatment of CRPC patients. Although the mechanisms of resistance are multi-factorial, the androgen axis still plays a major role in being active even after ADT.[2] Beside evidence that androgen receptor (AR) mutations, splice variants and increased copy number represent putative mechanisms of resistance to therapy,[3-6] the increased expression of enzymes able to facilitate the intratumoral

conversion of circulating adrenal androgen precursors to the active AR ligands could be responsible of the CRPC surviving mechanisms.[7] In CRPC cells the aldo-keto reductase 1C3 (AKR1C3 or 17 β -HSD5) is highly expressed.[5] This enzyme, which catalyzes the reduction of carbonyl substrates derived from both endogenous compounds and xenobiotics,[8] is a key player in several steps of the complex biochemical pathways leading to androgen production of potent AR ligands, as testosterone (T) and 5 α -dihydrotesterone (DHT).[8] Moreover, AKR1C3 has also been discovered to play roles in resistance to both hormone[5] and radiation therapy.[9] Potential clinical use of AKR1C3 inhibitors has been demonstrated as indomethacin, a potent but unselective AKR1C3 inhibitor, is able to circumvent resistance to the steroidogenic enzyme CYP17A1 abiraterone,[10] and to the AR antagonist enzalutamide.[11] Although a few recent studies indicate controversial observations about the *in vivo* effectiveness of AKR1C3-based therapies,[12-14] other studies strongly indicate AKR1C3 as a therapeutic target in PCa.[3, 15] Although several lead compounds have emerged,[16-19] the *pharmacopeia* still lacks an AKR1C3-targeted drug with clinical potential.




Figure 1. Chemical structures of flufenamic acid, indomethacin and AKR1C3 inhibitors recently deep evaluated.

In order to understand several key unanswered questions related to the *in vivo* application of AKR1C3 inhibitors, it is desirable to develop more potent, selective and drug-like AKR1C3 inhibitors. Amongst NSAIDs, flufenamic acid (FLU, Figure 1) potently inhibits AKR1C3 although it is known to suffer from COX off-target effects.[20, 21] Recently, we successfully applied a *scaffold hopping* strategy based on the replacement of quinolinecarboxylate moiety of brequinar with a hydroxyazolecarboxamidic scaffold for the design of new potent human dihydroorotate dehydrogenase (*h*DHODH) inhibitors.[22] In the present study, we applied a similar *scaffold hopping* strategy to the FLU benzoic acid moiety (Figure 2). Specifically, three hydroxyazoles (hydroxyfurazan, hydroxythiadiazole and a series of N-substituted hydroxyl-1,2,3-triazoles) were used to design compounds 1 - 8 (Figure 2). Due to their acidic properties their hydroxylazole scaffolds are widely deprotonated at physiological pH and are valid isosters of the carboxylic acid function as recently demonstrated by us.[23-25] In contrast to the hydroxyfurazan and hydroxythiadiazole scaffolds, the regiosubstitution of the nitrogen of the hydroxyltriazole ring allows the possibility to make a structural refinement,

which enables an opportunity to improve on binding pocket affinity. Accordingly, the substituents present on the triazole ring (Figure 2) were selected by their possibility of establishing interactions with sub-pocket 2 (SP2) of the AKR1C3 binding site[26] in an attempt to enhance target selectivity.





Figure 2. AKR1C3 inhibitors based on hydroxyazole scaffolds.

We here report on the design, synthesis and biological explorations of eight candidate structures (Figure 2), which supports the findings of AKR1C3-selective compounds with no off-target COX effect. Furthermore, the binding modes of the most representative molecules were suggested by computational modelling.

2. Result and discussion

2.1 Chemistry.

The methodology used for the synthesis of the target compounds is described in scheme 1. The first part of the work consisted in acquiring the protected benzyloxyazolecarboxylic acids (13, 16a-f, Scheme 1a and 1b) to couple to 3-trifluoromethylaniline (Scheme 1c). 4-Benzyloxy-1,2,5-oxadiazole-3-carboxylic acid 13 was prepared from 9 [25] by hydrolysis under basic condition to yield the corresponding acid 10. This latter was decarboxylated and dehydrated to the nitrile 11 then transformed into the methyl ester 12 by a Pinner reaction. Compound 13 was finally obtained by base-catalyzed hydrolysis of 12 (Scheme 1a). To obtain regio-substituted hydroxytriazole carboxylic acids 16 a-f, we recently presented a methodology starting from 14 as a common starting material.[23] This building block presents an alkylation pattern directed toward positions N_(b) and N_(c) of the triazole ring, leading to a mixture of two isomeric products. The isomeric mixtures were chromatographically resolved and each isomer structurally assigned on the basis of the heteronuclear 2D-NMR (HSQC and HMBC) and ¹³C-NMR spectra.[27] The hydrolysis of the obtained esters 15 a-f afforded the carboxylic acids of general structure 16 (Scheme 1b). Finally, carboxylic acids 13 and 16a-f were converted into the corresponding acyl chlorides and allowed to react with 3-trifluoromethylaniline to generate the amides 18 and 19a-f; these latter compounds were deprotected through catalytic hydrogenation to give the desired target compounds 1, 3 - 8 (Scheme 1c). Compound 2 was directly obtained from coupling of 4-hydroxy-1,2,5-thiadiazole-3-carboxylic acid 3unprotected 17[28] with trifluoromethylaniline. In this case, the protection of the hydroxyl group of 17 was avoided, which poses challenges to the removal of benzylic group already observed for other 4benzyloxy-1,2,5-thiadiazole-3-carboxamides[22]. The reaction of unprotected acid 17 with 3trifluoromethylaniline resulted a low yield passage, but allowed an easy purification of desired product 2.



Scheme 1. (a) 1) NaOH, EtOH, rt; 2) 2M HCl; (b) Ac_2O , 70°C; (c) NaH, dry MeOH, (d) 2M H_2SO_4 ; (e) RX, K_2CO_3 , CH_3CN , r.t.; (f) ClCOCOCl, dry DMF, dry THF, 0°C; (g) 3-trifluoromethylaniline, dry pyridine, dry THF, r.t.; (h) H_2 , Pd/C, THF, r.t..

2.2 AKR1C3 inhibition assays.

The activity of the compounds **1** - **8** and FLU as AKR1C3 inhibitors was initially tested by incubating a bacterial suspension containing recombinant AKR1C3 with radiolabeled [¹⁴C]-androstenedione in the presence of increasing inhibitor concentrations (Table 1). In comparison with FLU (IC₅₀ 8.63 μ M), the hydroxyfurazan **1**, the hydroxythiadiazole **2** and the N(b) methyl triazole **3** were found to be almost inactive while the N(c) methyl triazole **4** (IC₅₀ = 32.79 μ M) demonstrated weak inhibitory activity. Furthermore, the two cyclopropylmethyl triazoles **5** and **6**, the N(c) isomer resulted in more active compound than the N(b) analogue. As the binding site seems to better tolerate the N(c) substitution, we designed two more N(c) analogues with substituents of increasing size (**7** and **8**). Indeed N(c)

cyclopropylmethyl triazole **6** was shown to be more active than N(c) methyl triazole **4**, indicating the preference for lipophilic groups in that position. This hypothesis was confirmed as the benzyl **7** and 4-methoxylbenzyl **8** analogues displayed activity (IC₅₀s of 10.19 μ M and 3.56 μ M, respectively) comparable with FLU. Notably, with compound **8** was shown to be more potent than FLU under the conditions investigated.

	Bacterial suspension	Purified enzyme		
Compound	$AKR1C3 IC_{50} \pm SE (\mu M)^{a}$	$AKR1C3 IC_{50} \pm SE (\mu M)^{b}$	$\begin{array}{c} AKR1C2\\ IC_{50} \pm SE\\ (\mu M)^{b} \end{array}$	Ratio IC ₅₀ value (1C2:1C3)
FLU	8.63 ± 1.70	0.44 ± 0.023	0.53 ± 0.032	1.2
1	>50 (35.37% ± 3.37) ^c	n.d.	n.d.	n.d.
2	\geq 50 (47.22% ± 3.16) ^c	n.d.	n.d.	n.d.
3	>50 (18.47% ± 3.71) ^c	n.d.	n.d.	n.d.
4	32.79±1.10	n.d.	n.d.	n.d.
5	>50 (5.35% ± 1.44) ^c	n.d.	n.d.	n.d.
6	13.22 ± 0.81	1.60 ± 0.22	70.63 ± 6.32	44
7	10.19±1.47	0.48 ± 0.025	62.94 ± 5.13	131
8	3.56±0.08	0.31 ± 0.005	73.23 ± 8.67	236

Table 1. Inhibitory effect on AKR1C3 and AKR1C2 recombinant enzymes.

a) experiments performed with [¹⁴C]androstenedione as substrate; b) experiments performed with S-tetralol as substrate; c) % of inhibition \pm SE at 50 μ M. n.d: not determined.

The three most active compounds assayed in the bacterial suspension assay (6 - 8) were also assayed with AKR1C3 purified enzyme (Table 1) by following the oxidation of S-tetralol in the presence of NADP⁺. The inhibition pattern observed was similar to that observed with the bacterial suspension. Notably, compounds 7 and 8 were equipotent (IC₅₀ 0.48 μ M and 0.31 μ M, respectively) with FLU (IC₅₀ 0.44 μ M).

2.3. AKR1Cs selectivity and COX inhibition.

In PCa therapy, selective targeting of AKR1C3 over 1C2 is considered critical [29]: AKR1C2 share > 86% sequence identity with AKR1C3, and it is also involved in dihydrotestosterone inactivation, so its inhibition would be undesirable. Hence, the most active compounds 6 - 8 and FLU were assayed for their inhibitory properties using purified AKR1C2 incubated with S-tetralol (Table 1). Whereas the AKR1C2/C3 inhibition ratio of FLU was found to be 1.2, triazole analogues 7 and 8 were found to be 131 and 236-fold more

selective toward AKR1C3 inhibition. Next, the compounds **6** - **8** were assayed for their inhibitor effect on COX-1 and COX-2 off-target. Their activity, compared with different standards using ovine COX-1 (oCOX-1) and human COX-2 (hCOX-2) is reported in Table 2.

Table 2. COX-1 and COX-2 inhibitory activities of compounds 6, 7 and 8, compared with
flufenamic acid, indomethacin, celecoxib and rofecoxib.

Compound	oCOX1 IC ₅₀ ± SE (μ M)	hCOX2 IC ₅₀ ± SE (μ M)	Ratio IC ₅₀ value (COX1:AKR1C3)	Ratio IC ₅₀ value (COX2:AKR1C3)
FLU	14 ± 1	$> 100 \ (18\% \pm 2)^{a}$	32	> 227
6	$> 100 \ (17\% \pm 1)^{a}$	> 100 (9.6% ± 5.2) ^a	> 63	> 63
7	> 100 (15% ± 4) ^a	> 100 (7.5% ± 7.5) ^a	> 208	> 208
8	>100 (0) ^a	>100 (12% ± 4) ^a	> 322	> 322
Indomethacin	0.10 ± 0.01	0.61 ± 0.09	n.d.	n.d.
Celecoxib	14 ± 12	0.54 ± 0.12	n.d.	n.d.
Rofecoxib	>100 $(25 \pm 14)^{a}$	3.0 ± 1.0	n.d.	n.d.

a) % of inhibition \pm SE at 100 μ M. n.d: not determined.

Notably, compounds **6** - **8** did not display significant inhibitory activity on any of the two COX isoforms at the highest concentration tested (100 μ M). In contrast, FLU was shown to be effective in inhibiting COX-1 but not COX-2. Because contradictory data are reported in the literature for FLU and COX inhibition,[30] we validated our assay with indomethacin (time-dependent non-selective inhibitor[30]), celecoxib and rofecoxib (non-time-dependent for COX-1, time-dependent and selective for COX-2).[31, 32] Pleasingly, the COX 1/2 data obtained was consistent with inhibitory potencies reported in literature.[33, 34]

2.4 Antiproliferative activity and testosterone suppression.

We evaluated compounds 7, 8 and FLU in AKR1C3-expressing 22RV1 cells, which have been shown to possess resistance to abiraterone and enzalutamide.[10-12] The presence of AKR1C3 was confirmed using western blot (Figure 3A) before assessing the antiproliferative activity of three compounds using the SRB assay. Although compound 7 appeared to be a less potent inhibitor of AKR1C3 than both 8 and FLU, it was observed to be slightly more antiproliferative (Figure 3B). As AKR1C3 plays a key role in the production of testosterone in the androgen biosynthetic pathway, therapeutic intervention of this pathway is vital to effective treatment outcome. Given that 8 had a higher AKR1C3:AKR1C2 selectivity ratio than 7, we decided to evaluate the former for its ability to interfere with testosterone formation. In the presence of androstenedione (28 nM), testosterone production was increased > 200-fold in 22RV1 cells. When cells were treated with 8, a significant dosedependent impact on testosterone levels was observed (Figure 3C). In particular a 30% decrease testosterone production of the was observed when the cells were treated with 5 μ M solution of **8**. This decrease reach the 50% with a 10 μ M solution. of quindi la riduzione della formazione di testosterone osservata su enzima isolato si verifica anche su cellula.




Figure 3. Antiproliferative activity and testosterone production. Confirmation of AKR1C3 expression in 22RV1 cells by western blot (A) and antiproliferative activity of compounds **7**, **8** and FLU using the SRB assay (B). Evaluation of the inhibitory effect of compound **8** in androstenedione treated 22RV1 cells (C).

In order to evaluate a possible synergistic effect of our compounds with abiraterone and enzalutamide, experiments of co-treatment were performed. 22RV1 cells were treated with 60 μ M compound **8** with or without 10 μ M abiraterone for 72 h. The same experiment was carried out by treating cells with or without 20 μ M enzalutamide. As shown in Figure 4, abiraterone, enzalutamide and compound **8** had, each, limited effects on cell growth. When compound **8** was added together with either abiraterone or enzalutamide, the cell viability was reduced to 45% or 50%, respectively, suggesting a synergistic effect was achieved.




Figure 4. Effect of the co-treatment with compound 8 and abiraterone or enzalutamide on 22RV1 cells proliferation by SRB. Cells were treated with 60 μ M compound 8 with or

without 10 μ M abiraterone (or 20 μ M enzalutamide) for 72 h. Cell growth is expressed as % T/C (mean OD of treated cells/mean OD of control cells X 100).

2.5 Molecular modeling

To elucidate the observed activity of hydroxytriazole-based compounds, we performed a molecular docking study starting from the crystal protein complexed with FLU (PDB code: 1S2C) and using the Schrödinger QM-Polarized Ligand Docking protocol.[35] A stereo view showing FLU (orange) and compound 8 (grey) docked in the AKR1C3 binding site is presented in Figure 5. At first, self-docking procedure was successfully applied on FLU reproducing the crystallographic coordinate of FLU inside the binding site (Figure S1). The binding mode of FLU shows the carboxylate moiety interact with the so-called oxanion hole (OS) involving hydrogen bonds with Tyr55 and His117 and a water molecule with the NADP⁺ co-factor. The trifluoromethylphenyl moiety is directed toward the *sub-pocket* 1 (SP1), composed of Ser118, Asn167, Phe306, Phe311, Tyr216, Met120 and Tyr319, where it is involved in lipophilic interactions. The binding mode retrieved from docking studied on compound 8 revealed a high superimposition to FLU (Figure 5). In particular, the hydroxyl group present in the triazole ring was shown anchored in the OS, thereby mimicking the carboxylic group of FLU. The amide link present in compound 8 compared to the amine in FLU, extends the occupied space of trifluoromethylphenyl moiety inside SP1. This fact could explain the AKR1C3 selectivity of 8, as the AKR1C2 isoform is characterized by a smaller SP1.[29] Interestingly, the 4-methoxy-benzyl substituent of 8 has the ability to fit inside SP2, a small pocket part of the SC left unoccupied by FLU. Docking results suggest for the N(c) 4methoxy-benzyl substituent the presence of a π - π staking interaction with Trp227 (partial overlapping) and T-shape π - π staking with Trp86.




Figure 5. Stereo view of FLU (orange) and compound **8** (grey) docked in the AKR1C3 binding site. NADP⁺ is coloured in green.

3. Conclusions

This study has focused on a new generation of AKR1C3 inhibitors designed by utilizing a *scaffold hopping* approach to replace the benzoic acid moiety of FLU with hydroxylated azoles. The best compound of the series, the 4-methoxybenzyl substituted analogue **8**, was found to selectively inhibit AKR1C3 activity without any significant AKR1C2 and COX1/2 off-target effects. Compound **8** was also able to inhibit the testosterone production and cell

proliferation in AKR1C3-expressing 22RV1 CRPC cells. In addition, the inhibition of AKR1C3 activity by compound **8** partly resensitized 22RV1 cells to enzalutamide and abiraterone treatment. Taken together, the novel chemical scaffolds provides a promising starting point for the design of more potent AKR1C3 inhibitors with clinical potential.

4. Experimental section

4.1 Chemistry

4.1.1 General methods. All chemical reagents were obtained from commercial sources (Sigma Aldrich, Alfa Aesar) and used without further purification. Culture media were obtained from Sigma-Aldrich. Restriction enzymes, DNA polymerase and T4 DNA ligase were obtained from Promega. [4-14C]-androst-4-ene-3,17-dione (10 µCi/370 KBq, 53.6 mCi/mmol) was obtained from Perkin-Elmer. Analytical grade solvents (acetonitrile, diisopropyl ether, diethyl ether, dichloromethane [DCM], dimethylformamide [DMF], ethanol 99.8 % v/v, ethyl acetate, methanol [MeOH], petroleum ether b.p. 40 - 60°C [petroleum ether]) were used without further purification. When needed, solvents were dried on 4 Å molecular sieves. Tetrahydrofuran (THF) was distilled immediately prior to use from Na and benzophenone under N₂. Thin layer chromatography (TLC) on silica gel was carried out on 5 x 20 cm plates with 0.25 mm layer thickness to monitor the process of reactions. Anhydrous MgSO₄ was used as a drying agent for the organic phases. Purification of compounds was achieved with flash column chromatography on silica gel (Merck Kieselgel 60, 230-400 mesh ASTM) using the eluents indicated or by CombiFlash Rf 200 (Teledyne Isco) with 5–200 mL/min, 200 psi (with automatic injection valve) using RediSep Rf Silica columns (Teledyne Isco) with the eluents indicated. Purity was checked using two analytical methods. HPLC analyses were performed on an UHPLC chromatographic system (Perkin Elmer, Flexar). The analytical column was an UHPLC Acquity CSH Fluoro-Phenyl (2.1x100 mm, 1.7 µm particle size) (Waters). Compounds were dissolved in acetonitrile and injected through a 20 µl loop. The mobile phase consisted of acetonitrile / water with 0.1 % trifluoroacetic acid (ratio between 60 / 40 and 40 / 60, depending on the compound's retention factor). UHPLC analysis were run at flow rates of 0.5 mL/min, and the column effluent was monitored at 215 and 254 nm, referenced against a 360 nm wavelength. Purity of the synthetic intermediates varied between 90 % and 99 % purity. The biological experiments were employed on compounds with a purity of at least 95%. Melting points (m.p.) were measured on a capillary apparatus (Büchi 540) by placing the sample at a temperature 10° C below the m.p. and applying a heating rate of 1° C min⁻¹. All compounds were routinely checked by ¹H- and ¹³C-NMR and mass spectrometry. ¹H- and ¹³C-NMR spectra were performed on a Bruker Avance 300 instrument. For coupling patterns, the following abbreviations are used: br = broad, s = singlet, d = doublet, dd = doublet of doublets, t = triplet, q = quartet, m = multiplet. Chemical shifts (δ) are given in parts per million (ppm). MS spectra were performed on Finnigan-Mat TSQ-700 (70 eV, direct inlet for chemical ionization [CI]) or Waters Micromass ZQ equipped with ESCi source for electrospray ionization mass spectra. Compounds 9, [25] 15a, 15b, 15e, [23] 15c, 15d, 16a**d**,[22] **17**[28]were prepared following already described procedures.

4.1.2. 2-[4-(Benzyloxy)-1,2,5-oxadiazol-3-yl](hydroxyimino)acetic acid (10). 5M NaOH (8 mL) was added to a solution of 9 (2.21 g; 7.60 mmol) in ethanol (40 ml). The reaction mixture was stirred at room temperature for 24 h, then concentrated under reduced pressure. The crude material was dissolved in water (15 mL) and acidified with HCl until precipitation of the desired product occurred. The white obtained solid was a mixture of the two geometrical isomers in variable ratio. Yield 76 %. ¹H-NMR (300 MHz, most abundant isomer, DMSO-d₆): δ 5.32 (s, 2H), 7.29 - 7.32 (m, 5H), 13.59 (s, 1H), 13.80 (br s, 1H). ¹³C-

NMR (DMSO-d₆): δ 74.0, 128.7, 128.8, 128.9, 134.9, 136.5, 139.6, 162.6, 163.3. MS (CI) 263 [M + H]⁺.

4.1.3. 4-(*Benzyloxy*)-1,2,5-oxadiazole-3-carbonitrile (**11**). A solution of **10** (1.30 g; 4.94 mmol) in acetic anhydride (13 ml) was stirred at 70 °C for 2 h. The reaction mixture was cooled to r.t. and concentrated under reduced pressure to half volume, then poured into iced water (50 ml). The resulting mixture was stirred at room temperature for 30 min then extracted twice with diethyl ether. The organic collected layers were washed with saturated NaHCO₃, brine, dried with Na₂SO₄ and concentrated under reduced pressure. The oily crude was purified by flash chromatography using DCM as eluent to afford the title compound as a white solid (m.p. 44-45 °C). Yield 92 %. ¹H-NMR (300 MHz, CDCl₃): δ 5.35 (s, 2H), 7.34 - 7.42 (m, 5H). ¹³C-NMR (CDCl₃): δ 75.7, 106.3, 125.9, 129.0, 129.1, 129.8, 133.2, 164.6. MS (CI) 202 [M + H]⁺.

4.1.4. Methyl 4-(benzyloxy)-1,2,5-oxadiazole-3-carboxylate (12). Sodium hydride 60 % dispersion in mineral oil (398 mg) was added to a solution of 11 (1.00 g; 4.98 mmol) in dry methanol (10 mL). The reaction mixture was stirred under nitrogen atmosphere at 0 °C for 15 min, then allowed to reach room temperature and further stirred for 60 min. 2M H₂SO₄ (10 ml) was slowly added cooling the reaction mixture at 0°C. The resulting suspension was extracted with DCM. The organic layers were collected, dried and concentrated under reduced pressure. The crude material was purified by flash chromatography using petroleum ether / DCM 6:4 v/v as eluent, to afford the title compound as white solid (m.p. 45 °C). Yield 98 %. ¹H-NMR (300 MHz, CDCl₃): δ 3.91 (s, 3H), 5.35 (s, 2H), 7.29-7.43 (m, 5H). ¹³C-NMR (CDCl₃): δ 53.1, 74.4, 128.3, 128.6, 128.9, 134.0, 139.2, 157.4, 163.7. MS (CI) 235 [M + H]⁺.

4.1.5. Ethyl 4-(benzyloxy)-1-(4-methoxybenzyl)-1H-1,2,3-triazole-5-carboxylate (15f). Cs₂CO₃ (8.91 mmol) and 1-(chloromethyl)-4-methoxybenzene (1.23 g, 7.94 mmol) were added to a solution of 14 (1.10 g, 4.45 mmol) in CH₃CN (25 ml). The resulting mixture was stirred at room temperature for 16 hours. When the reaction was complete, the mixture was concentrated under reduced pressure, the crude product was extracted with EtOAc (50 mL) and the resulting suspension washed with 1M HCl (30 mL), 1M NaOH (30 mL) and brine. The organic phase was dried and concentrated under reduced pressure to afford a colorless oil. The latter showed two spots on TLC (eluent: petroleum ether /EtOAc 90/10 v/v) relative to the N_(b) and N_(c) substituted triazole isomers. The two isomers were separated using flash chromatography (eluent: petroleum ether / EtOAc 95/5 v/v). First eluted isomer, white solid (m.p. 76.5 - 78.7 °C). Yield 36 %. ¹H-NMR (300 MHz, DMSO-d₆): δ 1.24 (3H, t, J = 7.1 Hz), 3.72 (3H, s), 4.27 (2H, q, J = 7.1 Hz), 5.45 (2H, s), 5.73 (2H, s), 6.90 (2H, d, J = 8.5Hz), 7.18 (2H, d, J = 8.7 Hz), 7.29 - 7.50 (5H, m); ¹³C-NMR (DMSO-d₆): δ 13.9, 53.5, 55.1, 61.1, 71.1, 110.4, 114.1, 127.5, 127.6, 128.1, 128.4, 129.1, 136.4, 157.7, 159.1, 160.6. MS (ESI) 368 $[M + H]^+$. The second eluted isomer *ethyl* 5-(*benzyloxy*)-2-(4-methoxybenzyl)-2H-1,2,3-triazole-4-carboxylate was also isolated as a white solid and characterized. M.p. 80.7 -81.7 °C, from ethanol. Yield 60 %. ¹H-NMR (300 MHz, DMSO-d₆): δ 1.26 (t, J = 7.1 Hz, 3H), 3.74 (s, 3H), 4.25 (q, J = 7.1 Hz, 2H), 5.30 (s, 2H), 5.48 (s, 2H), 6.92 (d, J = 8.6 Hz, 2H), 7.27 (d, J = 8.6 Hz, 2H), 7.31 - 7.49 (m, 5H). ¹³C-NMR (DMSO-d₆): δ 14.0, 55.0, 58.3, 60.3, 71.7, 113.9, 123.0, 126.7, 127.8, 128.1, 128.3, 129.5, 135.8, 159.1, 159.4, 160.1. MS (ESI) 368 $[M + H]^+$.

4.1.6. General procedure for compounds 16e, 16f and 13.

6M NaOH (0.57 mL, 3.45 mmol) was added to a solution of the appropriate ester (1.15 mmol) in ethanol (25 mL) and the reaction mixture was stirred at room temperature until disappearance of starting material. The resulting solution was neutralized with 2M HCl, then concentrated under reduced pressure. 2M HCl was added until pH 1-2, observing

precipitation of a white solid. The solid was isolated by filtration to give the appropriate carboxylic acid.

4.1.6.1 4-(*Benzyloxy*)-1,2,5-oxadiazole-3-carboxylic acid (**13**). White solid (m.p. 106-107 °C from hexane/diisopropyl ether). ¹H-NMR (300 MHz, CDCl₃): δ 5.45 (s, 2H), 7.30 - 7.50 (m, 5H), 10.91 (br s, 1H). ¹³C-NMR (CDCl₃): δ 74.8, 128.7, 128.8, 129.1, 134.0, 139.1, 161.6, 163.9. MS (CI) 220 [M + H]⁺.

4.1.6.2 *1-Benzyl-4-(benzyloxy)-1H-1,2,3-triazole-5-carboxylic acid* (16e). White solid (m.p. 165.7 - 166.8°C). Yield 90 %. ¹H- NMR (300 MHz, DMSO-d₆): δ 5.44 (s, 2H), 5.82 (s, 2H), 7.14–7.52 (m, 10H), 13.66 ppm (br, 1H). ¹³C-NMR (DMSO-d₆): δ 53.7, 71.1, 111.2, 127.4, 128.0, 128.1, 128.4, 128.7, 128.7, 135.9, 136.4, 159.1, 160,4. MS (ESI) 310 [M + H]⁺.

4.1.6.3 4-(Benzyloxy)-1-(4-methoxybenzyl)-1H-1,2,3-triazole-5-carboxylic acid (16f). White solid (m.p. 179.1 - 180.5°C). Yield 84 %. ¹H-NMR (300 MHz, DMSO-d₆): δ 3.72 (s, 3H), 5.43 (s, 2H), 5.73 (s, 2H), 6.90 (d, J = 8.3 Hz, 2H), 7.18 (d, J = 8.3 Hz, 2H), 7.29 - 7.51 (m, 5 H), 13.62 (br, 1H). ¹³C-NMR (DMSO-d₆): δ 53.2, 55.1, 71.0, 111.0, 114.0, 127.7, 128.0, 128.1, 128.4, 129.1, 136.4, 159.1, 159.2, 160.5. MS (ESI) 340 [M + H]⁺.

4.1.7. General procedure for synthesis of amides 18 - 19a-f:

Dry DMF (26 μ L) and 2M oxalyl chloride in DCM (3.06 mmol, 1.53 mL) were added to a cooled (0°C) solution of the appropriate carboxylic acid (**13, 16 a - f**, 0.901 mmol) in dry THF (15 mL). The reaction was stirred for 3 hours at room temperature under nitrogen atmosphere. The solvent was evaporated under reduced pressure and the residue was dissolved in dry THF (this process was repeated for three times). The resulting acyl chloride was dissolved in dry THF (10 mL) and used without any further purification in the next step. Dry pyridine (219 μ L, 2.70 mmol) and 3-trifluoromethylaniline (113 μ L, 0.901 mmol) were added to the described solution. The reaction mixture was stirred for 12 hours at room temperature under nitrogen atmosphere. 0.5 M HCl was added to the resulting mixture, which was concentrated under reduced pressure. The resulting suspension was acidified with 0.5 M HCl to pH 2 and extracted with ethyl acetate (3 × 20 mL). The organic phases were collected, washed with brine, dried with Na₂SO₄, and the solvent was evaporated. The crude product was purified using flash chromatography (gradient of petroleum ether /ethyl acetate from 90/10 v/v to 70/30 v/v) to obtain the corresponding amide.

4.1.7.1. 4-(*Benzyloxy*)-*N*-(3-(*trifluoromethyl*)*phenyl*)-1,2,5-*oxadiazole*-3-*carboxamide* (18). Flash chromatography eluent: petroleum ether / ethyl acetate 9:1 v/v. White solid (m.p. 110.1 – 111.1 °C), yield 74 %. ¹H-NMR (300 MHz, CDCl₃): δ 5.48 (s, 2H), 7.39-7.52 (7H, m), 7.80 (d, *J* = 7.6 Hz, 1H), 7.91 (s, 1H), 8.58 (br s, 1H). ¹³C-NMR (75 MHz CDCl₃): δ 75.2, 116.9 (q, *J* = 3.8 Hz), 122.0 (q, *J* = 3.7 Hz), 123.1 (q, *J* = 0.8 Hz), 123.6 (q, *J* = 272.6 Hz), 128.7, 128.9, 129.3, 129.9, 131.70 (q, *J* = 32.1 Hz), 133.9, 137.0, 140.9, 153.8, 163.3. MS (CI) 364 [M + H]⁺.

4.1.7.2. 5-(Benzyloxy)-2-methyl-N-(3-(trifluoromethyl)phenyl)-2H-1,2,3-triazole-4carboxamide (19a). White solid (m.p. 110.2–112.3 °C). Yield 76 %. ¹H NMR (300 MHz, DMSO-d₆): δ 4.15 (s, 3H), 5.34 (s, 2H), 7.32–7.62 (m, 7H), 8.01 (d, J = 8.2 Hz, 1H), 8.26 (s, 1H), 10.48 (s, 1H). ¹³C NMR (DMSO-d₆): δ 42.4, 72.0, 116.2 (q, J = 4.1 Hz), 119.9 (q, J = 4.1 Hz), 123.6 (q, J = 1.2 Hz), 124.1 (q, J = 272.3 Hz), 125.5, 128.0, 128.2, 128.4, 129.3 (q, J = 31.4 Hz), 129.8, 136.0, 139.4, 158.1, 159.4. MS (ESI) 377 [M + H]⁺.

4.1.7.3. 4-(Benzyloxy)-1-methyl-N-(3-(trifluoromethyl)phenyl)-1H-1,2,3-triazole-5carboxamide (19b). White solid (m.p. 136.4 – 139.4°C). Yield 58 %. ¹H NMR (300 MHz, DMSO-d₆): δ 4.20 (s, 3H), 5.52 (s, 2H), 7.31–7.44 (m, 3H), 7.46–7.66 (m, 4H), 7.85 (d, J = 8.2 Hz, 1H), 8.08 (s, 1H), 9.90 (s, 1H). ¹³C NMR (DMSO-d₆): δ 37.9, 71.8, 114.2, 116.1 (q, *J* = 4.1 Hz), 120.6 (q, *J* = 3.8 Hz), 123.6 (q, *J* = 1.3 Hz), 123.9 (q, *J* = 272.3 Hz), 127.9, 128.2, 128.3, 129.5 (q, *J* = 31.8 Hz), 130.1, 136.2, 138.6, 155.9, 157.8. MS (ESI) 377 [M + H]⁺.

4.1.7.4. 5-(Benzyloxy)-2-(cyclopropylmethyl)-N-(3-(trifluoromethyl)phenyl)-2H-1,2,3triazole-4-carboxamide (19c). White solid (m.p. 79.0 - 80.7 °C). Yield 75 %. ¹H NMR (300 MHz, DMSO-d₆): δ 0.41–0.49 (m, 2H), 0.54–0.62 (m, 2H), 1.29–1.42 (m, 1H), 4.25 (d, J = 7.2 Hz, 2H), 5.35 (s, 2H), 7.32 – 7.62 (m, 7H), 8.01 (d, J = 8.2 Hz, 1H), 8.24 (s, 1H), 10.36 (s, 1H). ¹³C NMR (DMSO-d₆): δ 3.6, 10.7, 59.5, 72.0, 116.2 (q, J = 4.3 Hz), 119.9 (q, J = 4.1 Hz), 123.7 (q, J = 0.7 Hz), 124.1 (q, J = 272.4 Hz), 125.6, 128.2, 128.2, 128.4, 129.3 (q, J = 31.3 Hz), 129.8, 136.0, 139.4, 158.1, 159.2. MS (ESI) 417 [M + H]⁺.

4.1.7.5. 4-(Benzyloxy)-1-(cyclopropylmethyl)-N-(3-(trifluoromethyl)phenyl)-1H-1,2,3triazole-5-carboxamide (19d). White solid (m.p. 114.1–116.0 °C). Yield 63 %. ¹H NMR (300 MHz, DMSO-d₆): δ 0.37 - 0.45 (m, 2H), 0.48 - 0.57 (m, 2H), 1.27 - 1.44 (m, 1H), 4.47 (d, J = 7.3 Hz, 2H), 5.52 (s, 2H), 7.31 - 7.67 (m, 7H), 7.85 (d, J = 8.2 Hz, 1H), 8.08 (s, 1H), 10.06 (s, 1H). ¹³C NMR (DMSO-d₆): δ 3.7, 11.4, 54.9, 71.9, 113.5, 116.1 (q, J = 4.1 Hz), 120.7 (q, J = 4.3 Hz), 123.6 (q, J = 1.2 Hz), 124.0 (q, J = 272.1 Hz), 128.1, 128.3, 128.4, 129.6 (q, J = 31.5 Hz), 130.3, 136.3, 138.7, 156.1, 158.0. MS (ESI) 417 [M + H]⁺.

4.1.7.6. *1-Benzyl-4-(benzyloxy)-N-(3-(trifluoromethyl)phenyl)-1H-1,2,3-triazole-5-carboxamide* (19e). White solid (m.p. 152.2 - 154.2 °C). Yield 51 %. ¹H NMR (300 MHz, DMSO-d₆): δ 5.51 (s, 2H), 5.84 (s, 2H), 7.20 - 7.65 (m, 12H), 7.81 (d, J = 8.1 Hz, 1H), 8.00 (s, 1H), 10.00 (s, 1H). ¹³C NMR (DMSO-d₆): δ 53.4, 72.0, 113. 7, 116.1 (q, J = 3.8 Hz), 120.8 (q, J = 4.3 Hz), 123.6 (q, J = 0.7 Hz), 124.0 (q, J =, 272.3 Hz), 127.7, 128.1, 128.2, 128.4, 128.5, 128.8, 129.6 (q, J = 31.7 Hz), 130.3, 135.7, 136.2, 138.6, 155.9, 158.2. MS (ESI) 453 [M + H]⁺.

4.1.7.7 4-(Benzyloxy)-1-(4-methoxybenzyl)-N-(3-(trifluoromethyl)phenyl)-1H-1,2,3-triazole-5-carboxamide (19f). White solid (m.p. 138.9 – 140.3 °C). Yield 65 %. ¹H NMR (300 MHz, DMSO-d₆): δ 3.70 (s, 3H), 5.49 (s, 2H), 5.75 (s, 2H), 6.89 (d, J = 7.9 Hz, 2H), 7.24 (d, J = 7.9 Hz, 2H), 7.30–7.67 (m, 7H), 7.82 (d, J = 8.0 Hz, 1H), 8.01 (s, 1H), 10.00 ppm (s, 1H). ¹³C NMR (DMSO-d₆): 52.9, 55.1, 71.9, 113.5, 114.1, 116.1 (q, J = 3.0 Hz), 120.7 (q, J = 3.9 Hz), 123.6 (q, J = 0.5 Hz), 124.0 (q, J = 272.3 Hz) 127.5, 128.1, 128.3, 128.4, 129.5, 129.6 (q, J = 31.8 Hz), 130.3, 136.2, 138.6, 155.9, 158.2, 159.2 ppm. MS (ESI) 483 [M + H]⁺.

4.1.8. General hydrogenation procedure to obtain target compounds 1, 3 - 8.

The appropriate protected hydroxyazole (**18, 19a-f**, 0.400 mmol) dissolved in dry THF (20 mL) was hydrogenated in presence of Pd/C (45 mg) for 1 hour at atmospheric pressure. The reaction mixture was filtered off through a short layer of celite and the solvent was evaporated under reduced pressure yielding the desired compound.

4.1.8.1. 4-Hydroxy-N-(3-(trifluoromethyl)phenyl)-1,2,5-oxadiazole-3-carboxamide (1). White solid (m.p. 165.3 – 167.5 °C, from diisopropyl ether/hexane). Yield 62 %. ¹H-NMR (300 MHz, (CD₃)₂CO): δ 7.56 (d, J = 7.8 Hz, 1H), 7.69 (t, J = 8.0 Hz, 1H), 8.08 (d, J = 8.1 Hz, 1H), 8.30 (s, 1H), 10.24 (br s, 1H). ¹³C-NMR (75 MHz (CD₃)₂CO): δ 117.8 (q, J = 3.9 Hz), 122.3 (q, J = 3.8 Hz), 124.7, 124.9 (q, J = 272.1 Hz), 131.0, 131.5 (q, J = 32.1 Hz), 139.2, 142.2, 156.7, 163.5. MS (CI) 274 (M+1). ESI-HRMS (m/z) [M - H]⁻ calcd. for C₁₀H₅F₃N₃O₃ 272.0278, obsd. 272.0274.

4.1.8.2. 5-Hydroxy-2-methyl-N-(3-(trifluoromethyl)phenyl)-2H-1,2,3-triazole-4-carboxamide (3). White solid (m.p. 216.6 - 217.0 °C, from acetonitrile). Yield 97 %. ¹H NMR (300 MHz, DMSO-d₆): δ 4.07 (s, 3H), 7.43 (d, J = 7.8 Hz, 1H), 7.57, (t, J = 8.0 Hz, 1H), 8.00 (d, J = 8.1

Hz, 1H), 8.29 (s, 1H), 10.31 (s, 1H), 11.26 (br, 1H). ¹³C NMR (DMSO-d₆): δ 42.1, 116.2 (q, J = 4.1 Hz), 119.8 (q, J = 3.8 Hz), 123.6 (q, J = 1.1 Hz), 124.2 (q, J = 272.3 Hz), 124.9, 129.4 (q, J = 31.6 Hz), 129.8, 139.5, 158.8, 158.9. ESI-HRMS (m/z) [M - H]⁻ calcd. for C₁₁H₈F₃N₄O₂ 285.0605, obsd. 285.0594.

4.1.8.3. 4-Hydroxy-1-methyl-N-(3-(trifluoromethyl)phenyl)-1H-1,2,3-triazole-5-carboxamide (4). White solid (m.p. 235.6 - 241.0 °C, from acetonitrile). Yield 96 %. ¹H NMR (300 MHz, DMSO-d₆): δ 4.19 (s, 3H), 7.47 (d, J = 7.7 Hz, 1H), 7.59 (t, J = 8.0 Hz, 1H), 7.83 (d, J = 8.2 Hz, 1H), 8.20 (s, 1H), 9.90 (s, 1H), 12.98 (br s, 1H). ¹³C NMR (DMSO-d₆): δ 38.6, 111.9, 116.0 (q, J = 4.1 Hz), 120.3 (q, J = 3.9 Hz), 123.6 (q, J = 1.3 Hz), 124.0 (q, J = 272.4 Hz), 129.6 (q, J = 31.7 Hz), 130.1, 138.8, 156.6, 158.1. ESI-HRMS (m/z) [M - H]⁻ calcd. for C₁₁H₈F₃N₄O₂ 285.0605, obsd. 285.0605.

4.1.8.4. 2-(Cyclopropylmethyl)-5-hydroxy-N-(3-(trifluoromethyl)phenyl)-2H-1,2,3-triazole-4carboxamide (5). White solid (m.p. 187.3 - 188.4 °C, from acetonitrile). Yield 96 %. ¹H NMR (300 MHz, DMSO-d₆): δ 0.38 - 0.47 (m, 2H), 0.54–0.64 (m, 2H), 1.25–1.40 (m, 1H), 4.18 (d, J = 7.2 Hz, 2H), 7.43 (d, J = 7.8 Hz, 1H), 7.57 (t, J = 8.0 Hz, 1H), 8.01 (d, J = 8.2 Hz, 1H), 8.27 (s, 1H), 10.20 (s, 1H), 11.30 (br, 1H). ¹³C NMR (DMSO-d₆): δ 3.6, 10.7, 59.3, 116.2 (q, J = 3.6 Hz), 119.8 (q, J = 3.7 Hz), 123.7 (q, J = 1.4 Hz), 124.1 (q, J = 272.3 Hz), 124.8, 129.4 (q, J = 31.5 Hz), 129.8, 139.4, 158.6, 159.0. ESI-HRMS (m/z) [M - H]⁻ calcd. for C₁₄H₁₂F₃N₄O₂ 325.0910, obsd. 325.0907.

4.1.8.5. 3-(Cyclopropylmethyl)-4-hydroxy-N-(3-(trifluoromethyl)phenyl)-1H-1,2,3-triazole-4carboxamide (6). White solid (m.p. 226.9 - 229.0 °C, from acetonitrile). Yield 79 %. ¹H NMR (300 MHz, DMSO-d₆): δ 0.35–0.45 (m, 2H), 0.47–0.57 (m, 2H), 1.30–1.45 (m, 1H), 4.47 (d, *J* = 7.3 Hz, 2H), 7.48 (d, *J* = 7.7 Hz, 1H), 7.60 (t, *J* = 8.0 Hz, 1H), 7.83 (d, *J* = 8.2 Hz, 1H), 8.20 (s, 1H), 10.01 (s, 1H), 13.05 (br s, 1H). ¹³C NMR (DMSO-d₆): δ 3.49, 11.2, 55.3, 110.9, 115.9 (q, *J* = 4.0 Hz), 120.3 (q, *J* = 3.9 Hz), 123.5 (q, *J* = 1.1 Hz), 123.9 (q, *J* = 272.4 Hz), 129.5 (q, *J* = 31.6 Hz), 130.0, 138.7, 156.5, 158.2. ESI-HRMS (m/z) [M - H]⁻ calcd. for C₁₄H₁₂F₃N₄O₂ 325.0907, obsd. 325.0911.

4.1.8.6. *1-Benzyl-4-hydroxy-N-(3-(trifluoromethyl)phenyl)-1H-1,2,3-triazole-5-carboxamide* (7). White solid (m.p. 222.2 - 224.6 °C, from acetonitrile). Yield 97 %. ¹H NMR (300 MHz, DMSO-d₆): δ 5.84 (s, 2H), 7.23–7.39 (m, 5 H), 7.46 (d, J = 7.9 Hz, 1H), 7.57 (t, J = 8.0 Hz, 1H), 7.82 (d, J = 8.1 Hz, 1H), 8.13 (s, 1H), 9.88 (s, 1H), 12.73 (br, 1H). ¹³C NMR (DMSO-d₆): δ 53.6, 111.3, 116.2 (q, J = 4.3 Hz), 120.5 (q, J = 4.3 Hz), 123.8 (q, J = 1.3 Hz), 124.1 (q, J = 272.4 Hz), 127.6, 128.1, 128.7, 129.6 (q, J = 31.7 Hz), 130.2, 135.8, 138.7, 156.5, 158.3. ESI-HRMS (m/z) [M - H]⁻ calcd. for C₁₇H₁₂F₃N₄O₂ 361.0907, obsd. 361.0908.

4.1.8.7. 4-Hydroxy-1-(4-methoxybenzyl)-N-(3-(trifluoromethyl)phenyl)-1H-1,2,3-triazole-5carboxamide (8). White solid (m.p. 215.5 - 217.7 °C, from acetonitrile). Yield 98 %. ¹H NMR (300 MHz, DMSO-d₆): δ 3.71 (s, 3H), 5.75 (s, 2H), 6.90 (d, J = 8.6 Hz, 2H), 7.25 (d, J = 8.6 Hz, 2H), 7.47 (d, J = 7.8 Hz, 1H), 7.58 (t, J = 7.9 Hz, 1H), 7.83 (d, J = 8.2 Hz, 1H), 8.14 (s, 1H), 9.90 (s, 1H), 12.88 (br, 1H). ¹³C NMR (DMSO-d₆): δ 53.2, 55.1, 111.1, 114.1, 116.1 (q, J = 4.1 Hz), 120.5 (q, J = 3.9 Hz), 123.8 (q, J = 1.5 Hz), 124.1 (q, J = 272.1 Hz), 127.6, 129.4, 129.6 (q, J = 30.4 Hz), 130.2, 138.7, 156.5, 158.4, 159.1. ESI-HRMS (m/z) [M - H]⁻ calcd. for C₁₈H₁₄F₃N₄O₃ 391.1024, obsd. 391.1031.

4.1.9. 4-Hydroxy-N-[3-(trifluoromethyl)phenyl]-1,2,5-thiadiazole-3-carboxamide (2). The compound was obtained following the general procedure for synthesis of amides starting from 17.[28] Flash chromatography eluent: DCM / methanol 90/10 v/v. White solid (m.p. 177.6 – 178.9 °C, from diisopropyl ether). Yield 40 %.¹H-NMR (300 MHz, CD₃OD): δ 7.46 (1H, d, *J* = 7.9 Hz), 7.56 (1H, t, *J* = 8.0 Hz), 7.97 (1H, d, *J* = 8.2 Hz), 8.20 (1H, s). ¹³C-NMR

(75 MHz CD₃OD) δ 118.3 (q, J = 4.0 Hz), 122.3 (q, J = 4.0 Hz), 125.1 (q, J = 1.3 Hz), 125.5 (q, J = 272.5 Hz), 130.8, 132.2 (q, J = 32.3 Hz), 139.7, 140.8, 160.7, 166.0. MS (CI) 290 [M + H]⁺. ESI-HRMS (m/z) [M - H]⁻ calcd. for C₁₀H₅F₃N₃O₂S 288.0049, obsd. 288.0047.

4.2. Expression and purification of recombinant human AKR1C3 and AKR1C2.

Plasmid coding for human AKR1C3 was kindly provided by Prof. J. Adamski (Institute of Experimental Genetics, Genome Analysis Center, Neuherberg, Germany). The cDNA showed one mutation His5Gln in comparison to the NCBI sequence. This conservative mutation is described in the literature as a single nucleotide polymorphism (SNPs) and seems to be very common (refSNP: rs12529). Clone RC213538 containing human AKR1C2 cDNA was obtained by Origene. cDNA was sequenced by the C.R.I.B.I. – BMR Servizio Sequenziamento DNA, Padova (Italy). Then, it was amplified by PCR and, subsequently, subcloned using Xho I and Sal I into the same pGEX 2T- modified plasmid vector (kindly provided by Prof. J. Adamski), used for AKR1C3.

Plasmids coding for AKR1C3 and AKR1C2 were transformed into Escherichia coli BL21 (DE) Codon Plus RP (Agilent Technologies). For the protein expression, bacteria cells expressing AKR1C3 and AKR1C2 were grown in YT2X media supplemented with ampicillin at 37°C with continuous shaking. At OD600 nm = 0.6 the expression was induced by IPTG (0.5 mM). Bacteria were harvested 2 h after induction by centrifugation and stored at -20°C until use. For the AKR1C3 and AKR1C2 purification, bacteria were suspended in PBS supplemented with lysozyme (0.1 mg/ml) and protease inhibitor (Sigma). Then, bacteria were lysed by four freeze-thaw cycles followed by DNA-digestion with benzonase (25 U) in presence of MgCl₂ 5 mM. After centrifugation of the lysate for 30 min at 4°C and 13,000 x g, the supernatant was collected. Then, AKR1C3 and AKR1C2 were affinity purified via N-terminal GST-tag on glutathione (GT) sepharose (GE-Healthcare) and cleaved of by thrombin according to the manufacturer's protocol. Expression and purification was monitored by SDS-PAGE.

4.3 In vitro AKR1C3 and AKR1C2 inhibition assays.

The inhibition assays were carried out by using bacterial suspension or purified enzymes. In the screening of AKR1C3 inhibitors, bacteria expressing AKR1C3 were suspended in 100 mM phosphate buffer pH 6.6 without lysis. The bacterial suspension (about 15 μ g of proteins) was incubated with [¹⁴C]androstenedione (6 X 10⁻⁴ μ Ci) in the presence of Tween80 (0.1 mg/mL), ATP (1 mM), MgCl₂ (1 mM) and a NADPH generating system (1 mM NADP⁺, 3 mM glucose-6-phosphate and 3 units of G-6-P dehydrogenase) for 30 min at 30°C with vigorous shaking. Inhibitors, when present, were added as solution in ETOH (10% v/v). The enzymatic reaction was stopped by heating at 80 °C for 10 min. After extracting two times with ethyl ether (1.5 mL), the solvent was evaporated and the extract was separated on TLC silica gel plates using chloroform/ethyl acetate (4:1; v/v) as a developing system. Percent conversion of the labeled substrate to testosterone was estimated by integration from radioactivity scans with a System 200 Imaging Scanner (Hewlett-Packard, Palo Alto, CA, USA).

In order to study the selectivity versus AKR1C2 of the active inhibitors of AKR1C3, the purified recombinant enzymes were used. The activity of the inhibitors was evaluated by using as a substrate S-tetralol in 96-well format. The reaction was fluorimetrically (exc/em; 340 nm/ 460 nm) monitored by the measurement of NADPH production on a "Ensight" plate reader (Perkin Elmer) at 37°C. Assay mixture contained S-tetralol (in ETOH), inhibitor (in ETOH), 100 mM phosphate buffer, pH 7, 200 μ M NADP⁺, and purified recombinant enzyme (30 μ) in a final volume of 200 μ l and 10% ETOH. The S-tetralol concentration used in the AKR1C2 and AKR1C3 inhibition assay were 15 microM and 160 microM, respectively, the

some as the Km described for the respective isoforms under the same experimental conditions. Percent inhibition with respect to the controls containing the same amount of solvent, without inhibitor, was calculated from the initial velocities, obtained by linear regression of the progress curve, at different concentrations of inhibitor. The IC₅₀ values were obtained using PRISM 7.0, GraphPad Software. The values are the means of two separate experiments each carried out in triplicate.

4.4 COX1 and COX2 inhibition assays

References and selected compounds were tested for their ability to inhibit COX-1 and COX-2 using a COX (ovine/human) Inhibitor Screening Assay Kit (Cayman Chemical Co., Ann Arbor, MI), following manufacturer's instructions. The assay directly measured $PGF_{2\alpha}$ by $SnCl_2$ reduction of COX-derived PGH_2 produced in the COX reaction. The prostanoid product was quantified *via* enzyme immunosorbent assay (ELISA); absorbance measurements were obtained on a PerkinElmer 2030 Multilabel Reader. IC₅₀ values were obtained by linear regression using PRISM 7.0, GraphPad Software. Results were calculated as mean value \pm standard error (SE) of at least three experiments.

4.5 Tumor cell lines and cell culture.

22RV1 castration-resistant prostate cancer cells were used. Cells were grown in RPMI supplemented with 10% (v/v) fetal calf serum, 2% (v/v) penicillin-streptomycin, 0.03% L-glutamine and maintained at 37 °C in a humidified atmosphere containing 5% CO₂.

4.6 *Cell proliferation assay.*

Cell growth inhibition was evaluated by sulforhodamine B colorimetric proliferation assay (SRB assay) modified by Vichai and Kirtikara.[36] 22RV1 cells were seeded into 96-well plates in RPMI containing 10% charcoal stripped serum, 2 % (v/v) penicillin-streptomycin and 0.03% L-glutamine, at a density of 10,000 cells/well and incubated at 37 °C with 5% CO₂ for 24 hours to allow cellular adhesion. Various dilutions of inhibitors in ethanol were added in triplicate, and incubated for 72 h. Control cells were incubated with the same final concentration of ethanol (maximum concentration 1% v/v). The assay was done as previously described.[37] For co-treatment experiments, 22RV1 cells were treated with abiraterone (10 μ M) or enzalutamide (20 μ M) with or without compound 8 (60 μ M) for 72 h. The statistical analysis were performed with PRISM 7.0, GraphPad Software. The values are the means of two separate experiments each carried out in triplicate.

4.7 Inhibition of AKR1C3-Mediated Production of Testosterone in 22RV1 cells.

22RV1 cells were seeded into 96-well plates in RPMI media containing 10% charcoal stripped serum, 2% (v/v) penicillin-streptomycin and 0.03% L-glutamine, at a density of 30,000 cells per well, and were incubated at 37° C with 5% CO₂ for 24 hours. Compound **8** was added to the wells at 4 different concentrations and incubated for 1 hour. Equimolar (28nM) concentration of androstenedione was then added to the wells. The plate was returned to the incubator for a further 24h. Cell supernatant was removed for analysis of testosterone by ELISA following the manufacturer's guide (Testosterone ELISA kit was purchased from Cayman Chemical Company). The ELISA plate was read at a wavelength of 405nM on a microplate reader. Analysis was performed using the Cayman Chemical Company's online available analysis tool and data was quantitated against a standard curve generated in ELISA buffer. Cross reactivity to androstenedione was accounted for by adding these to cell-free wells of the ELISA plate. The statistical analysis were performed with PRISM 7.0, GraphPad Software. The values are the means of two separate experiments each carried out in triplicate.

25 ug of total protein lysate was loaded for analysis by western blot. For detection of AKR1C3, 1:10,000 dilution of mouse monoclonal anti-AKR1C3 (Sigma Aldrich) was prepared in blocking buffer and added to the membrane with an overnight incubation at 4 °C on a shaker. Mouse B-actin (Sigma Aldrich) was used as internal control with a dilution of 1:20,000 in blocking buffer, with overnight incubation at 4 °C on a shaker. Membranes were subsequently washed with PBST and incubated with secondary goat anti-mouse antibody (Thermo Fisher Scientific) at a dilution of 1:500 for 1 hour at room temperature on a shaker. Membranes were washed and exposed to UV light to detect target bands and captured using a digital camera.

4.9 Molecular Modeling.

The structures of compounds 6, 7 and 8, as well as the structures of the lead compound Flufenamic Acid, were built in their dissociated forms using the 2D Sketcher tool implemented in Maestro GUI. For each compound, an advanced conformational search was performed using OPLS 2005 as Force Field and setting 1000 maxium steps for each run. Quantum mechanics/molecular mechanics (QM/MM) docking was performed using Schrödinger QM-Polarized Ligand Docking protocol (QPLD).[35] For this purpose, the Xray crystallographic structure of AKR1C3 was retrieved from RCSB Database (PDB code: 1S2C) and the generated conformers were docked. Before docking, the crystal structure of the protein underwent an optimization process using the Protein Preparation Wizard tool, implemented in MaestroTM GUI. Missing hydrogen atoms were added and bond orders were assigned. Then, DMS, non-structural water molecules and impurities (such as solvent molecules) were removed. The water 2152 was mantained in the binding site because its important water network, [26] also the cofactor NAP and the co-crystalized ligand Flufenamic Acid were maintained. Reorienting automatically optimized the hydrogen bond network: hydroxyl and thiol groups, amide groups of asparagine (Asn) and glutamine (Gln), and the imidazole ring in histidine (His). Moreover, the protonation states prediction of His-aspartic acid (Asp), glutamic acid (Glu), and tautomeric states of His-were accomplished using PROPKA.[™] Finally, a restrained minimization of the protein structure was accomplished by converging heavy atoms to a 0.30 Å RMSD. A grid of 10 Å x 10 Å x 10 Å (x, y, and z) was created and centered on the co-crystalized ligand Flufenamic acid. The ligand was extracted from the structure and used for docking validation. The QPLD protocol was carried out using Glide Extra Precision (XP) mode, setting QM Level to Accurate (B3LYP functional, 6-31G*/LACVP* basis set, ultrafine SCF accuracy level). In the QPLD procedure, after the first XP docking run, QM-derived charge is calculated for the top five poses of each compound in the field of the receptor. Then, a new XP docking is performed with new QM charges calculated. Finally, re-docking and re-scoring were performed, keeping the 10 highest ranked poses.

AUTHOR INFORMATION

Corresponding Authors: * Phone: +39-0116707993. Fax: +39-0116707687, *e*-mail: <u>marco.lolli@unito.it</u>. Phone: +39-0116706864 . *e*-mail: <u>simona.oliaro@unito.it</u>. Notes. The authors declare no competing financial interest.

ABBREVIATIONS USED

Aldo-keto reductase 1C3 isoform (AKR1C3), Prostate cancer (PCa), androgen deprivation therapy (ADT), castration-resistant prostate cancer (CRPC), androgen receptor (AR), flufenamic acid (FLU), sub-pocket 2 (SP2), sub-pocket 1 (SP1), cyclooxygenase (COX), aldo-keto reductase 1C2 isoform (AKR1C2), dichloromethane (DCM), dimethylformamide (DMF), methanol (MeOH), Quantum mechanics/molecular mechanics (QM/MM), QM-Polarized Ligand Docking (QPLD), Palladium on carbon (Pd/C), hexadeuterodimethyl

sulfoxide (DMSO-d₆), deuterochloroform (CDCl₃), tetradeuteromethanol (CD₃OD), deuterated acetone (CD₃)₂CO).

ACKNOWLEDGEMENTS

We thank Prof Norman J. Maitland (University of York) for provision of the 22RV1 PC cell line. We also thank Prof. J. Adamski (Institute of Experimental Genetics, Genome Analysis Center, Neuherberg, Germany) for supplying the plasmid coding for human AKR1C3. This research was financially supported by the University of Turin (*Ricerca Locale grant* 2014 and 2015) and Prostate Cancer UK grant S12-027. Authors wish to thank dr. Livio Stevanato for performing all the NMR experiments and for maintenance of the instrument.

Appendix A. Supplementary data

Supplementary data related to this article can be found at: XXXXXX

References

[1] R.L. Siegel, K.D. Miller, A. Jemal, Cancer statistics, 2016, CA: A Cancer Journal for Clinicians, 66 (2016) 7-30.

[2] Y. Imamura, M.D. Sadar, Androgen receptor targeted therapies in castration-resistant prostate cancer: Bench to clinic, International Journal of Urology, 23 (2016) 654-665.

[3] T. Seisen, M. Roupret, F. Gomez, G.G. Malouf, S.F. Shariat, B. Peyronnet, J.P. Spano, G. Cancel-Tassin, O. Cussenot, A comprehensive review of genomic landscape, biomarkers and treatment sequencing in castration-resistant prostate cancer, Cancer Treat Rev, 48 (2016) 25-33.

[4] J. Kumagai, J. Hofland, S. Erkens-Schulze, N.F.J. Dits, J. Steenbergen, G. Jenster, Y. Homma, F.H. de Jong, W.M. van Weerden, Intratumoral conversion of adrenal androgen precursors drives androgen receptor-activated cell growth in prostate cancer more potently than de novo steroidogenesis, Prostate (Hoboken, NJ, U. S.), 73 (2013) 1636-1650.

[5] T.M. Penning, Mechanisms of drug resistance that target the androgen axis in castration resistant prostate cancer (CRPC), Journal of Steroid Biochemistry and Molecular Biology, 153 (2015) 105-113.

[6] M. Sakai, D.B. Martinez-Arguelles, A.G. Aprikian, A.M. Magliocco, V. Papadopoulos, De novo steroid biosynthesis in human prostate cell lines and biopsies, Prostate (Hoboken, NJ, U. S.), 76 (2016) 575-587.

[7] W. Zhang, Y. Meng, N. Liu, X.F. Wen, T. Yang, Insights into chemoresistance of prostate cancer, International Journal of Biological Sciences, 11 (2015) 1160-1170.

[8] T.M. Penning, The aldo-keto reductases (AKRs): Overview, Chem Biol Interact, 234 (2015) 236-246.

[9] S.Q. Sun, X. Gu, X.S. Gao, Y. Li, H. Yu, W. Xiong, H. Yu, W. Wang, Y. Li, Y. Teng, D. Zhou, Overexpression of AKR1C3 significantly enhances human prostate cancer cells resistance to radiation, Oncotarget, 7 (2016) 48050-48058.

[10] C. Liu, C.M. Armstrong, W. Lou, A. Lombard, C.P. Evans, A.C. Gao, Inhibition of AKR1C3 Activation Overcomes Resistance to Abiraterone in Advanced Prostate Cancer, Mol. Cancer Ther., 16 (2017) 35-44.

[11] C. Liu, W. Lou, Y. Zhu, J.C. Yang, N. Nadiminty, N.W. Gaikwad, C.P. Evans, A.C. Gao, Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer, Cancer Res., 75 (2015) 1413-1422.

[12] Y.D. Yin, M. Fu, D.G. Brooke, D.M. Heinrich, W.A. Denny, S.M.F. Jamieson, The activity of SN33638, an inhibitor of AKR1C3, on testosterone and 17β -estradiol production and function in castration-resistant prostate cancer and ER-positive breast cancer, Frontiers in Oncology, 4 JUN (2014).

[13] W. Zhou, P. Limonta, AKR1C3 Inhibition Therapy in Castration-Resistant Prostate Cancer and Breast Cancer: Lessons from Responses to SN33638, Frontiers in Oncology, 4 (2014) 162.

[14] Y. Loriot, K. Fizazi, R.J. Jones, J. Van den Brande, R.L. Molife, A. Omlin, N.D. James, E. Baskin-Bey, M. Heeringa, B. Baron, G.M. Holtkamp, T. Ouatas, J.S. De Bono, Safety, tolerability and anti-tumor activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study, Invest. New Drugs, 32 (2014) 995-1004.

[15] A. Egan, Y. Dong, H. Zhang, Y. Qi, S.P. Balk, O. Sartor, Castration-resistant prostate cancer: Adaptive responses in the androgen axis, Cancer Treatment Reviews, 40 (2014) 426-433.

[16] A. Adeniji, M.J. Uddin, T. Zang, D. Tamae, P. Wangtrakuldee, L.J. Marnett, T.M. Penning, Discovery of (R)-2-(6-Methoxynaphthalen-2-yl)butanoic Acid as a Potent and Selective Aldo-keto Reductase 1C3 Inhibitor, Journal of Medicinal Chemistry, 59 (2016) 7431-7444.

[17] T. Zang, K. Verma, M. Chen, Y. Jin, P.C. Trippier, T.M. Penning, Screening baccharin analogs as selective inhibitors against type 5 17β -hydroxysteroid dehydrogenase (AKR1C3), Chem.-Biol. Interact., 234 (2015) 339-348.

[18] J.U. Flanagan, G.J. Atwell, D.M. Heinrich, D.G. Brooke, S. Silva, L.J.M. Rigoreau, E. Trivier, A.P. Turnbull, T. Raynham, S.M.F. Jamieson, W.A. Denny, Morpholylureas are a new class of potent and selective inhibitors of the type 5 $17-\beta$ -hydroxysteroid dehydrogenase (AKR1C3), Bioorganic and Medicinal Chemistry, 22 (2014) 967-977.

[19] A.J. Liedtke, A.O. Adeniji, M. Chen, M.C. Byrns, Y. Jin, D.W. Christianson, L.J. Marnett, T.M. Penning, Development of Potent and Selective Indomethacin Analogues for the Inhibition of AKR1C3 (Type 5 17β -Hydroxysteroid Dehydrogenase/Prostaglandin F Synthase) in Castrate-Resistant Prostate Cancer, J. Med. Chem., 56 (2013) 2429-2446.

[20] T.M. Penning, P. Talalay, Inhibition of a major NAD(P)-linked oxidoreductase from rat liver cytosol by steroidal and nonsteroidal anti-inflammatory agents and by prostaglandins, Proc Natl Acad Sci U S A, 80 (1983) 4504-4508.

[21] A.O. Adeniji, B.M. Twenter, M.C. Byrns, Y. Jin, M. Chen, J.D. Winkler, T.M. Penning, Development of Potent and Selective Inhibitors of Aldo-Keto Reductase 1C3 (Type 5 17β -Hydroxysteroid Dehydrogenase) Based on N-Phenyl-Aminobenzoates and Their Structure-Activity Relationships, J. Med. Chem., 55 (2012) 2311-2323.

[22] S. Sainas, A.C. Pippione, M. Giorgis, E. Lupino, P. Goyal, C. Ramondetti, B. Buccinna, M. Piccinini, R.C. Braga, C.H. Andrade, M. Andersson, A.C. Moritzer, R. Friemann, S. Mensa, S. Al-Kadaraghi, D. Boschi, M.L. Lolli, Design, synthesis, biological evaluation and X-ray structural studies of potent human dihydroorotate dehydrogenase inhibitors based on hydroxylated azole scaffolds, Eur J Med Chem, 129 (2017) 287-302.

[23] A.C. Pippione, F. Dosio, A. Ducime, A. Federico, K. Martina, S. Sainas, B. Frolund, M. Gooyit, K.D. Janda, D. Boschi, M.L. Lolli, Substituted 4-hydroxy-1,2,3-triazoles: synthesis, characterization and first drug design applications through bioisosteric modulation and scaffold hopping approaches, Medchemcomm, 6 (2015) 1285-1292.

[24] M.L. Lolli, S.L. Hansen, B. Rolando, B. Nielsen, P. Wellendorph, K. Madsen, O.M. Larsen, U. Kristiansen, R. Fruttero, A. Gasco, T.N. Johansen, Hydroxy-1,2,5-oxadiazolyl Moiety as Bioisoster of the Carboxy Function. Synthesis, Ionization Constants, and Pharmacological Characterization of γ -Aminobutyric Acid (GABA) Related Compounds, J. Med. Chem., 49 (2006) 4442-4446.

[25] M.L. Lolli, C. Giordano, D.S. Pickering, B. Rolando, K.B. Hansen, A. Foti, A. Contreras-Sanz, A. Amir, R. Fruttero, A. Gasco, B. Nielsen, T.N. Johansen, 4-Hydroxy-1,2,5-oxadiazol-3-yl Moiety as Bioisoster of the Carboxy Function. Synthesis, Ionization Constants, and Molecular Pharmacological Characterization at Ionotropic Glutamate Receptors of Compounds Related to Glutamate and Its Homologues, J. Med. Chem., 53 (2010) 4110-4118.

[26] J.U. Flanagan, Y. Yosaatmadja, R.M. Teague, M.Z.L. Chai, A.P. Turnbull, C.J. Squire, Crystal structures of three classes of non-steroidal anti-inflammatory drugs in complex with aldo-keto reductase 1C3, PLoS One, 7 (2012) e43965.

[27] A. Ducime, New bioisosteric applications of hydroxylated azoles in Drug Design, PhD Thesis, in: Dipartimento di Scienza e Tecnologia del Farmaco, Turin University, Turin, 2016.

[28] D. Lehmann, R. Eckardt, G. Faust, W. Fiedler, W. Poepel, H.J. Jaensch, H.J. Heidrich, D. Lohmann, Preparation of 3-carboxy-4-hydroxy-1,2,5-thiadiazole as a drug intermediate, in, VEB Arzneimittelwerk, Ger. Dem. Rep. . 1989, pp. 7 pp.

[29] M.C. Byrns, Y. Jin, T.M. Penning, Inhibitors of type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3): overview and structural insights, J Steroid Biochem Mol Biol, 125 (2011) 95-104.

[30] M. Ouellet, M.D. Percival, Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms, Biochemical Journal, 306 (1995) 247-251.

[31] J.K. Gierse, C.M. Koboldt, M.C. Walker, K. Seibert, P.C. Isakson, Kinetic basis for selective inhibition of cyclo-oxygenases, Biochemical Journal, 339 (1999) 607-614.

[32] C.C. Chan, S. Boyce, C. Brideau, S. Charleson, W. Cromlish, D. Ethier, J. Evans, A.W. Ford-Hutchinson, M.J. Forrest, J.Y. Gauthier, R. Gordon, M. Gresser, J. Guay, S. Kargman, B. Kennedy, Y. Leblanc, S. Leger, J. Mancini, G.P. O'Neill, M. Ouellet, D. Patrick, M.D. Percival, H. Perrier, P. Prasit, I. Rodger, P. Tagari, M. Therien, P. Vickers, D. Visco, Z. Wang, J. Webb, E. Wong, L.J. Xu, R.N. Young, R. Zamboni, D. Riendeau, Rofecoxib [vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)- furanone]: A potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles, Journal of Pharmacology and Experimental Therapeutics, 290 (1999) 551-560.

[33] G. Eren, S. Ünlü, M.T. Nuñez, L. Labeaga, F. Ledo, A. Entrena, E. Banolu, G. Costantino, M.F. Ahin, Synthesis, biological evaluation, and docking studies of novel heterocyclic diaryl compounds as selective COX-2 inhibitors, Bioorganic and Medicinal Chemistry, 18 (2010) 6367-6376.


[34] J.J. Talley, D.L. Brown, J.S. Carter, M.J. Graneto, C.M. Koboldt, J.L. Masferrer, W.E. Perkins, R.S. Rogers, A.F. Shaffer, Y.Y. Zhang, B.S. Zweifel, K. Seibert, 4-[5-Methyl-3-phenylisoxazol-4-yl]-benzenesulfonamide, Valdecoxib: A potent and selective inhibitor of COX-2 [4], Journal of Medicinal Chemistry, 43 (2000) 775-777.

[35] S. Schrödinger Suite 2017-1 QM-Polarized Ligand Docking protocol; Glide, LLC, New York, NY, 2017; Jaguar, Schrödinger, LLC, New York, NY, 2017; QSite, Schrödinger, LLC, New York, NY, 2017., in.

[36] V. Vichai, K. Kirtikara, Sulforhodamine B colorimetric assay for cytotoxicity screening, Nat Protoc, 1 (2006) 1112-1116.

[37] S. Sapino, E. Ugazio, L. Gastaldi, I. Miletto, G. Berlier, D. Zonari, S. Oliaro-Bosso, Mesoporous silica as topical nanocarriers for quercetin: characterization and in vitro studies, Eur J Pharm Biopharm, 89 (2015) 116-125.

Table of Contents Graphic



Highlights

- 1) New AKR1C3 inhibitors were designed and synthetized using hydroxyazoles scaffolds.
- 2) Modeling was used for speculate the interaction with the AKR1C3 binding site.
- 3) New compounds were assayed for AKR1C3 selectivity and cell-based activities.
- 4) Cpd 8 shows synergistic effect in combination with abiraterone and enzalutamide